ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,967.84
-0.22%
US Tech 100
21,102.40
-0.27%
Dow Jones
42,206.82
0.08%
Brent Oil
77.695
-0.01%
Bitcoin
100,633.96
-0.37%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. ImmunityBio Inc (IBRX) Quote

ImmunityBio Inc

ImmunityBio Inc (IBRX)

NASDAQ
2.87
0.035
(1.23%)
Closed June 22 4:00PM
15 min delayed - Upgrade to Realtime
2.8899
0.0199
(0.69%)
After Hours: 7:58PM
15 min delayed - Upgrade to Realtime

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.8899
Bid
2.60
Ask
3.51
Volume
9,118,393
2.83 Day's Range 2.93
1.83 52 Week Range 7.63
Market Cap
2.551B
Previous Close
2.835
Open
2.86
Last Trade
200
@
2.8899
(formt)
Last Trade Time
Financial Volume
$ 26,095,794
VWAP
2.8619
Average Volume (3m)
9,414,066
Shares Outstanding
882,620,409
Dividend Yield
-
PE Ratio
-69.33
Earnings Per Share (EPS)
-0.47
Revenue
14.75M
Net Profit
-413.56M

About ImmunityBio Inc

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.immunitybio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IBRX. The last closing price for ImmunityBio was $2.84. Over the last year, ImmunityBio shares have traded in a share price range of $ 1.83 to $ 7.63.

ImmunityBio currently has 882,620,409 shares outstanding. The market capitalization of ImmunityBio is $2.50 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -69.33.

Ask ADVFN Intelligence (AI)

ImmunityBio (IBRX) Options Flow Summary

IBRX Options Flow

Overall Flow

Bullish

Net Premium

31k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

IBRX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 20 2025
IBRX (1.23%)

Form 8-K - Current report
Edgar (US Regulatory)
June 20 2025
IBRX (1.23%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 12 2025
IBRX (1.23%)

Form 8-K - Current report
Edgar (US Regulatory)
May 12 2025
IBRX (1.23%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1401-4.623762376243.033.242.7797281452.99119307CS
40.299911.57915057922.593.762.43105939783.00305675CS
12-0.5201-15.25219941353.413.761.8394140662.67252834CS
260.22998.642857142862.664.271.8376644752.82515442CS
52-3.5401-55.05598755836.437.631.8360768123.54237285CS
156-0.4401-13.21621621623.3310.531.2145857483.9274159CS
260-33.6601-92.093296853636.5540.8341.2136380954.57599091CS

IBRX - Frequently Asked Questions (FAQ)

What is the current ImmunityBio share price?
The current share price of ImmunityBio is $ 2.8899
How many ImmunityBio shares are in issue?
ImmunityBio has 882,620,409 shares in issue
What is the market cap of ImmunityBio?
The market capitalisation of ImmunityBio is USD 2.5B
What is the 1 year trading range for ImmunityBio share price?
ImmunityBio has traded in the range of $ 1.83 to $ 7.63 during the past year
What is the PE ratio of ImmunityBio?
The price to earnings ratio of ImmunityBio is -69.33
What is the cash to sales ratio of ImmunityBio?
The cash to sales ratio of ImmunityBio is 1.95k
What is the reporting currency for ImmunityBio?
ImmunityBio reports financial results in USD
What is the latest annual turnover for ImmunityBio?
The latest annual turnover of ImmunityBio is USD 14.75M
What is the latest annual profit for ImmunityBio?
The latest annual profit of ImmunityBio is USD -413.56M
What is the registered address of ImmunityBio?
The registered address for ImmunityBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the ImmunityBio website address?
The website address for ImmunityBio is www.immunitybio.com
Which industry sector does ImmunityBio operate in?
ImmunityBio operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NXTTNext Technology Holding Inc
$ 3.44
(158.65%)
13.84M
WHLRWheeler Real Estate Investment Trust Inc
$ 7.15
(109.06%)
52.35M
CTORCitius Oncology Inc
$ 2.63
(69.68%)
20.77M
LUCYInnovative Eyewear Inc
$ 3.52
(54.39%)
111.21M
LGCLLucas GC Ltd
$ 1.0407
(53.16%)
11.17M
NWGLNature Wood Group Ltd
$ 1.71
(-69.63%)
3.99M
ICUSeaStar Medical Holding Corporation
$ 0.351
(-64.05%)
21.9M
MBRXMoleculin Biotech Inc
$ 0.259999
(-55.40%)
16.84M
RGCRegencell Bioscience Holdings Ltd
$ 37.50
(-40.81%)
2.22M
CGTLCreative Global Technology Holdings Ltd
$ 1.4399
(-36.57%)
6.71M
HCTIHealthcare Triangle Inc
$ 0.0297
(12.08%)
583.72M
DFLIDragonfly Energy Holdings Corporation
$ 0.245
(12.39%)
334.37M
GNLNGreenlane Holdings Inc
$ 0.009
(-13.04%)
262.88M
NVDANVIDIA Corporation
$ 143.85
(-1.12%)
242.95M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.359
(-0.09%)
193.97M

IBRX Discussion

View Posts
axelvento axelvento 5 days ago
$IBRX At 9:52 on the podcast : "We have now tested 8,000 doses safely"

https://www.youtube.com/live/BW6SlvIxzKg
👍️0
axelvento axelvento 1 week ago
$IBRX June 18,2025 (Wednesday) - Annual Meeting of Shareholders PSS has to meet or beat our expectations and deliver very encouraging news/guidance for 2H of 2025.

https://ir.immunitybio.com/events/event-details/2025-annual-meeting-stockholders
💯 1 😃 1
work-n-hard work-n-hard 2 weeks ago
Agreed....again. They fact that they were having a private conversation, not just part of a large group, really struck me as a possible game changer.
👍️0
NRS NRS 2 weeks ago
Good call on yesterday! I took half off today. I took half off on 5/20 and replaced them with the same amount on around 5/30, once I was confident the rise in price would continue. I'm very enthused with the CEO meeting Trump and the King in Saudi. That convinced me the future on this one is solid.
👍️0
work-n-hard work-n-hard 2 weeks ago
Agreed. Took a few off the table yesterday, but only to turn around and use it to buy more lower.
More shares without paying for it.
I call that a win. lol
👍️0
NRS NRS 2 weeks ago
I think we're going into a pull back for the next few days, similar to 5/20, but will push higher than current prices after that.
👍️0
work-n-hard work-n-hard 2 weeks ago
You'll notice that it dropped off after I posted, so it was pretty steady for a couple of days, before it wasn't.
And I've been holding for about 3 months, that's A LOT of patience for me. lol
👍️0
westjtter westjtter 2 weeks ago
I don't know about steady....lets let this one consolidate for awhile...patience grasshopper...patience!
👍️0
work-n-hard work-n-hard 2 weeks ago
On a steady march to $5.
👍️0
axelvento axelvento 2 weeks ago
There is a biologic for anemia: EPOGEN. And one for neutropenia: NUEPOGEN. But never in the history of medicine one for Lymphopenia, the NK and T cells that matter! Now there is. NCT# to enable access to physicians and patients who need it. Cancer Bioshield pic.twitter.com/3nKVDrsGPE— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 10, 2025
🎯 1 👍️ 1 🔝 1
axelvento axelvento 2 weeks ago
https://clinicaltrials.gov/study/NCT06956547?cond=Lymphopenia
🤑 1 🤠 1
work-n-hard work-n-hard 2 weeks ago
IBRX Up 8% just today. 3.4 pps
👍️0
axelvento axelvento 2 weeks ago
The power of natural killer cells (NK cells) - Nature's first responder to cancer and infection. The Cancer Bioshield enables your body to be the factory and protect the immune system that matters

https://t.co/6gRIo5A7ao— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 7, 2025
😃 1 🤑 1
glenn1919 glenn1919 2 weeks ago
IBRX..........................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
👍️ 1
axelvento axelvento 2 weeks ago
Thanks. Here is a video of the patients still doing well with wonderful quality of life... alive and cancer free now 10 years plus. T cell memory. The disease is the dysfunctional immune system. The power of the cancer bioshield. https://t.co/h2xccvSq2W pic.twitter.com/M34dMH7Tg4— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 6, 2025
😀 1 🤠 1
axelvento axelvento 2 weeks ago
The European Medicines Agency (EMA) is anticipated to provide a decision on the marketing authorization application for ANKTIVA®
September 2025
UK The assessment is expected to be completed by the fourth quarter of 2025
#IBRX
👆️ 1 💯 1
westjtter westjtter 2 weeks ago
Well the battle for the $3's has now begun in a very serious way......the defence of the $3 mark has been courageous but it appears that the front line may be showing some cracks....hang on as this could get interesting as the first strategic battles are the most difficult to overcome....once $3 is in the rear view mirror, the other defenses will fall much easier...we will see.
👍️ 2
axelvento axelvento 3 weeks ago
Do we already have the key to curing cancer?

Do we already have the key to curing cancer?

Dr. Patrick Soon-Shiong joined me to share his unique insight on cancer and cancer treatments.

Listen to the FULL episode ⬇️https://t.co/YaGD2n9t8k pic.twitter.com/gaTrFXxvmC— Charlie Kirk (@charliekirk11) June 3, 2025
😃 1 🤣 1 ✌️ 1
jondoeuk jondoeuk 3 weeks ago
In this paper, they identify IGSF8 as a new innate immune checkpoint that allows cancer cells with antigen presentation defects to suppress NKs https://www.cell.com/cell/abstract/S0092-8674(24)00355-6

Cancer cells can develop multiple other mechanisms to evade NKs as well, such as this https://www.cell.com/cell-reports/fulltext/S2211-1247(24)01206-3
👍️0
axelvento axelvento 3 weeks ago
This patient has remained cancer-free for over six years and continues to enjoy a high quality of life as of June 2025.

THAT’S PRACTICALLY UNHEARD OF FOR PANCREATIC CANCER AND UNDERSCORES THE POTENTIAL FOR LONG-TERM SUCCESS.
🎯 1 👍️ 1 💯 1 🔝 1
dstock07734 dstock07734 3 weeks ago
See the survival for the most difficult cancer. The most-life threatening subtype has the longest survival.Are NK cells one part of the striking group commanded by DCs?



👍️0
axelvento axelvento 3 weeks ago
pancreatic cancer- remained in remission for over six years and maintains a high quality of life.
ANKTIVA

https://pmc.ncbi.nlm.nih.gov/articles/PMC11954496/

$IBRX
👌 2 ✌️ 1
axelvento axelvento 3 weeks ago
At the 2025 ASCO Annual Meeting, ImmunityBio presented landmark results showing that reversing lymphopenia with ANKTIVA and CAR-NK
therapy significantly prolonged median overall survival in third- to sixth-line metastatic pancreatic cancer patients

https://meetings.asco.org/abstracts-presentations/246953

$IBRX
💯 1
axelvento axelvento 3 weeks ago
Expanded Access finally approved! Now the next challenge is to provide insight that lymphopenia is the root cause of early mortality and that it can be reversed by protecting NK and T cells from high dose chemo, radiation and checkpoint therapy #Bioshield https://t.co/sfcD60zp2b— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 2, 2025
👀 1 💯 1
axelvento axelvento 3 weeks ago
At ASCO25, academia finally wakes up to what I've been saying for decades. "Every 10% decrease in ALC from baseline was associated with a 48% increase risk of death" Lymphocytes matter. The Cancer Bioshield protects. Can't wait to share with FDA this month. pic.twitter.com/eUWEfJCIpi— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 2, 2025
👆️ 1
axelvento axelvento 3 weeks ago
Another great ASCO25 poster highlighting why lymphocyte counts matter. The highest mortality with low lymphocyte count regardless of tumor mutation. Our poster on pancreatic cancer shows longer OS with higher lymphocyte counts

Another great ASCO25 poster highlighting why lymphocyte counts matter. The highest mortality with low lymphocyte count regardless of tumor mutation. Our poster on pancreatic cancer shows longer OS with higher lymphocyte counts @Mustafajsalehmd @DrChoueiri @SashaGusevPosts pic.twitter.com/RaBqxi9pHg— Dr. Pat Soon-Shiong (@DrPatSoonShiong) June 3, 2025
💯 1 🔝 1
axelvento axelvento 3 weeks ago
Until this authorization, no approved therapy existed to directly treat lymphopenia.

$IBRX
👆️ 1 😁 1
dstock07734 dstock07734 3 weeks ago
$IBRX is no revolution.

See in the figure? The NK cells are just part of the immune cell army activated by DCVax-L.

DCVax-L is the biggest breakthrough in medicine ever!

👍️0
axelvento axelvento 3 weeks ago
FDA authorizes ANKTIVA for lymphopenia in cancer patients

https://www.stocktitan.net/news/IBRX/immunity-bio-receives-fda-expanded-access-authorization-for-landmark-r7jen8fl8qgp.html
👍️ 1 😃 1 😎 1
work-n-hard work-n-hard 3 weeks ago
Seems as though, that Right to Try, which was signed under the same administration last go-round, would apply here?
👍️0
axelvento axelvento 3 weeks ago
The Immuno-Revolution in the Desert: How ImmunityBio's Saudi Pact Could Usher in a New Era of Cancer Care—and Profits


https://www.ainvest.com/news/immuno-revolution-desert-immunitybio-saudi-pact-usher-era-cancer-care-profits-2505/
👀 1 😄 1
axelvento axelvento 3 weeks ago
GREAT - Requests for #BioShield to @cssifm has been incredible - a desperate need. Team working hard to respond to every #Cancer request. Each page represents a single patient request, now in the 1000s, working w/ FDA on Expanded Access @DrMakaryFDA @RobertKennedyJr @realDonaldTrump pic.twitter.com/DX4gaH91p1— Dr. Pat Soon-Shiong (@DrPatSoonShiong) May 30, 2025
👍️0
axelvento axelvento 3 weeks ago
we are on the right track$

Exciting progress with Qatar to advance Cancer #BioShield in the Middle East. USA will lead the world in driving health as a bridge to peace. @realDonaldTrump https://t.co/W0PQvP5Xyg— Dr. Pat Soon-Shiong (@DrPatSoonShiong) May 29, 2025
👍️ 1 🤙 1
axelvento axelvento 3 weeks ago
This is so Huge, Anktiva Cancer Treatment/Cure, No more Burning Radiation, No more Rat Poison Chemo, this has got to be a Top subject FDA Every Day....
👍️0
work-n-hard work-n-hard 3 weeks ago
Still holding here, just waiting for the day when they can no longer play with this stock and it moves back to at least double from here.....and that's just the start of it.
👍️0
axelvento axelvento 4 weeks ago
$IBRX At 26:30 mins) PSS reports that BioShield will be brought to Saudi Arabia, the Middle East and Africa within 90 days!

https://www.youtube.com/live/rcflKJwXsA4
🔝 1 😃 1
axelvento axelvento 4 weeks ago
$IBRX
Unlike conventional treatments including chemotherapy and radiation that kill and suppress natural killer immune cells and thus paradoxically catalyze further spread, the BioShield protects and activates the immune system’s natural killer cells and T cells to restore immune function and prolong life.


https://www.biospace.com/press-releases/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshield-platform-in-the-middle-east
👍️0
axelvento axelvento 4 weeks ago
KFSHRC Signs Five International Agreements to Advance Medical Innovation at Saudi-U.S. Investment Forum

The signed agreements include a memorandum of understanding with Cleveland Clinic focused on autism and neuroscience, a tripartite agreement with Qiddiya Investment Company and Cleveland Clinic in sports medicine and performance, a collaboration with Germfree for advanced laboratory development, an agreement with Medtronic to supply cardiac center equipment and establish a new catheterization unit, and a memorandum of understanding with ImmunityBio—alongside the King Abdullah International Medical Research Center and the Ministry of Investment—to develop a national biotechnology platform in immunotherapy for cancer and infectious diseases.

https://www.kfshrc.edu.sa/en/news/2025/05/kfshrc-signs-five-international-agreements-to-advance-medical-innovation
👆️ 2 🔝 2
axelvento axelvento 1 month ago
volume today
🙌 1 ✌️ 1
axelvento axelvento 1 month ago
multibagger$$$$$$
👍️ 1 🤑 1 🤠 1
work-n-hard work-n-hard 1 month ago
I'm just waiting for the day that "The Letter" gets turned around. That should be a easy $5.
And when some really big announcement happens, who knows?
💯 1 🔝 1
axelvento axelvento 1 month ago
$IBRX Looks like we are going to see $3 today again
👆️ 1 👍️ 1 🤑 1
axelvento axelvento 1 month ago
Piper Sandler raises ImmunityBio stock rating, target to $5
👋 1 💯 1
work-n-hard work-n-hard 1 month ago
https://immunitybio.com/careers/

Like the one woman said, concerning coming to work there and getting in on the ground floor, so to will it be for investors of this stock.
One day we could be talking about "back when this stock was being sold for under $3".
JMHO

https://immunitybio.com/
👍️0
axelvento axelvento 1 month ago
In March 2025, the Company completed its submission to the FDA of the sBLA for the use of ANKTIVA plus BCG in BCG-unresponsive NMIBC in the papillary indication. On May 2, 2025, and notwithstanding the FDA’s invitation to submit the sBLA articulated by its leadership at the January Meeting, the FDA delivered an RTF letter. The Company together with its consultants who attended the January 2025 meeting were shocked by this inconsistent response and have requested an urgent meeting with the Agency to resolve this issue.

“We are fully determined to work with the FDA as quickly as possible, including having already requested a Type A meeting, to explore the best path forward.

_We are waiting for an answer_
👍️0
axelvento axelvento 1 month ago
IBRX multibagger$$$$$$$$
👍️0
axelvento axelvento 1 month ago
$IBRX 74% held by Insiders.
👌 1 🤙 1
work-n-hard work-n-hard 1 month ago
ImmunityBio (IBRX) Moves to Buy: https://finviz.com/news/58821/immunitybio-ibrx-moves-to-buy-rationale-behind-the-upgrade
👍️0
axelvento axelvento 1 month ago
Huge market for Lymphopenia! Absolute Lymphocyte Count and Neutrophil-to-Lymphocyte Ratios: Overlooked Biomarkers in Cancer Treatment Outcomes - Patrick Soon-Shiong

https://www.urotoday.com/video-lectures/non-muscle-invasive-bladdercancer/video/mediaitem/4819-absolute-lymphocyte-count-and-neutrophil-to-lymphocyte-ratios-overlooked-biomarkers-in-cancer-treatment-outcomes-patrick-soon-shiong.html
👆️ 1 💯 1
work-n-hard work-n-hard 1 month ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176195537
👍️0

Your Recent History

NASDAQ
IBRX
ImmunityBio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads